Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2021-N-0525]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA, we, or Agency) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Submit written comments (including recommendations) on the collection of information by July 26, 2021.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to 
                        *https://www.reginfo.gov/​public/​do/​PRAMain.*
                         Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0435. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Prescription Drug Marketing; Administrative Procedures, Policies, and Requirements—21 CFR Part 203 OMB Control Number 0910-0435—Extension This information collection supports FDA regulations codified at part 203 (21 CFR part 203) implementing the Prescription Drug Marketing Act of 1987 (PDMA) and the Prescription Drug Amendments of 1992. The Federal Food, Drug, and Cosmetic Act, as amended by the PDMA, establishes requirements for the following: Reimportation of prescription drugs.
                The sale, purchase, or trade of or the offer to sell, purchase, or trade, prescription drugs that were purchased by hospitals or health care entities or donated to charitable organizations.
                The distribution of prescription drug samples by mail, common carrier, or another means of distribution.
                Applications for reimportation to provide emergency medical care.
                An appeal from an adverse decision by the district office.
                Drug sample storage and handling.
                Fulfillment houses, shipping and mailing services, comarketing agreements, and third-party recordkeeping.
                Donation of drug samples to charitable institutions. The PDMA was enacted, in part, because insufficient safeguards existed over the drug distribution system to prevent the introduction and retail sale of substandard, ineffective, or counterfeit drugs. The PDMA is intended to ensure that drug products purchased by consumers are safe and effective, and to avoid an unacceptable risk that counterfeit, adulterated, misbranded, subpotent, or expired drugs are sold. The applicable regulations in part 203 include reporting and recordkeeping requirements intended to help achieve the following goals: (1) To ban the reimportation of prescription drugs produced in the United States, except when reimported by the manufacturer or under FDA authorization for emergency medical care; (2) to ban the sale, purchase, or trade, or the offer to sell, purchase, or trade, of any prescription drug sample; (3) to limit the distribution of drug samples to practitioners licensed or authorized to prescribe such drugs or to pharmacies of hospitals or other healthcare entities at the request of a licensed or authorized practitioner; (4) to require licensed or authorized practitioners to request prescription drug samples in writing; (5) to mandate storage, handling, and recordkeeping requirements for prescription drug samples; and (6) to prohibit, with certain exceptions, the sale, purchase, or trade, or the offer to sell, purchase, or trade, of prescription drugs that were purchased by hospitals or other healthcare entities or that were donated or supplied at a reduced price to a charitable organization. In the 
                    **Federal Register**
                     of March 12, 2021 (86 FR 14128), we published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. We estimate the burden of the information collection as follows: Table 1—Estimated Annual Reporting Burden 1
21 CFR section; activity
Number of
                             respondents
Number of
                             responses 
                             per 
                             respondent
Total
                             annual 
                             responses
Average burden
                             per response
Total hours203.11; reimportation applications
1
1
1
0.5 (30 minutes)
2
                             1203.37(a); falsification of records
140
21.4
3,000
0.25 (15 minutes)
750203.37(b); loss or theft of samples
140
178.57
25,000
0.25 (15 minutes)
6,250203.37(c); conviction of representatives
1
1
1
1
1203.37(d); contact person
20
1
20
0.25 (15 minutes)
5Total


28,022

7,0071
                         There are no capital costs or operating and maintenance costs associated with this collection of information.2
                         Rounded to the nearest whole number.
 
 
 Table 2—Estimated Annual Recordkeeping Burden 1
21 CFR section; activity
Number of
                             recordkeepers
Number of
                             records per 
                             
                                recordkeeper 2
Total
                             annual 
                             records
Average
                             burden per 
                             recordkeeping
Total hours**Subpart C: Sales restrictions**203.23(a) and (b); returns
2,200
71.9909
158,380
0.25 (15 minutes)
39,595203.23(c); documentation of storage of returns
2,200
71.9909
158,380
0.08 (~6 minutes)
12,670**Subpart D: Samples**203.30-203.39; documentation regarding sample distributions
140
202
28,280
~.07-.08 (~4-5 minutes)
2,121Total


345,040

54,3861
                         There are no capital costs or operating and maintenance costs associated with this collection of information.2
                         Rounded to the nearest whole number.
 Based on a review of Agency data, we assume 2,200 respondents may incur burden resulting from the information collection activity associated with the requirements in § 203.23(a) through (c). A total of 140 pharmaceutical companies have submitted information to the Agency on drug sample distribution under part 203. Those same respondents also have recordkeeping requirements under part 203. Our estimate of the burden of the average burden per recordkeeping reflects a cumulative average to cover all applicable requirements. Since our last request for OMB approval, we have adjusted our estimate of the overall burden downward to reflect a decrease of 2,567,713 hours and 64,432,232 records annually. We attribute this adjustment to a more accurate reflection of the number of respondents to the information collection and clarification that burden attributable to requirements of the Drug Quality and Security Act are not included in this information collection. Dated: June 21, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy.


[FR Doc. 2021-13597 Filed 6-24-21; 8:45 am] BILLING CODE 4164-01-P